Nanoparticles in Ocular Drug Delivery Systems

Hugo Almeida; Ana Catarina Silva

doi:10.3390/pharmaceutics15061675

Nanoparticles in Ocular Drug Delivery Systems

Pharmaceutics. 2023 Jun 8;15(6):1675. doi: 10.3390/pharmaceutics15061675.

Authors

Hugo Almeida^{1

2

3}, Ana Catarina Silva^{1

2

4}

Affiliations

¹ UCIBIO (Research Unit on Applied Molecular Biosciences), REQUIMTE (Rede de Química e Tecnologia), MEDTECH (Medicines and Healthcare Products), Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
² Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
³ Mesosystem Investigação & Investimentos by Spinpark, Barco, 4805-017 Guimarães, Portugal.
⁴ FP-BHS (Biomedical and Health Sciences Research Unit), FP-I3ID (Instituto de Investigação, Inovação e Desenvolvimento), Faculty of Health Sciences, University Fernando Pessoa, 4249-004 Porto, Portugal.

Abstract

Conventional ophthalmic formulations lack a prolonged drug release effect and mucoadhesive properties, decreasing their residence time in the precorneal area and, therefore, in drug penetration across ocular tissues, presenting low bioavailability with a consequent reduction in therapeutic efficacy [...].

Publication types

Editorial

Grants and funding

The Applied Molecular Biosciences Unit—UCIBIO—which is financed by national funds from Fundação para a Ciência e a Tecnologia—FCT—(UIDP/04378/2020 and UIDB/04378/2020), supported this work.